Compare TG Therapeutics Inc (TGTX) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs US Bancorp — how do they compare? TG Therapeutics Inc trades at $55.37 (market cap $8.16B), while US Bancorp trades at $57.08 (market cap $88.86B). The key difference: US Bancorp is far larger — about 10.9× TG Therapeutics Inc's market cap, and US Bancorp pays a 3.79% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and US Bancorp for 97 Days on average.
| TGTX | USB | |
|---|---|---|
Market Cap | $8.16B | $88.86B |
Volume | 1,735,121 | 8,869,993 |
Sector | Health | Financials |
52-Week High | $59.06 | $65.42 |
52-Week Low | $26.94 | $45.28 |
Typical Hold Time | 16 Days | 97 Days |
Enterprise Value | $8.37B | $118.35B |
Dividend Yield | — | 3.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $53.34, up 0.74% on the day, amid a bearish technical signal despite a neutral oscillator reading. The company reported strong revenue growth, with 2025 revenue at $616.29M and net income of $447.18M, though recent quarterly EPS misses and a negative net cash flow of $100.70M in 2025 highlight operational challenges. Positive news includes BRIUMVI capturing significant market share and institutional buying interest.
The outlook is mixed; robust analyst consensus (84.62% buy ratings) and a $80.50 price target suggest upside, but risks include ongoing litigation, earnings volatility, and high valuation multiples. Key catalysts are subcutaneous BRIUMVI data and potential acquisition interest, though execution risks remain.
U.S. Bancorp (USB) trades at $57.03, up 1.53% today, with a bearish technical signal but strong fundamentals including 11.38 P/E ratio and 27.61% net margin. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Recent news highlights dividend increases and strong fee revenue momentum, while technical indicators show the stock testing key support levels near $55-56.
USB presents a value opportunity with attractive valuation metrics and consistent earnings beats, though near-term technical weakness and regulatory uncertainties pose risks. The 51% analyst buy rating and $69.94 consensus target suggest 23% upside potential, supported by dividend growth and solid banking operations in a rising rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
